FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170446002> ?p ?o ?g. }

• W3170446002 endingPage "1073" @default.
• W3170446002 startingPage "1073" @default.
• W3170446002 abstract "1073 Background: Paclitaxel, a foundation treatment in MBC, is hydrophobic and must be formulated for IV administration with Cremophor EL, increasing the risk of infusion reactions and necessitating pre-treatment with corticosteroids and antihistamines. Paclitaxel cannot be administered orally because it is a substrate for P-gp. The oral bioavailability of paclitaxel is improved when administered 1 hour after the highly selective, potent, and minimally absorbed P-gp inhibitor encequidar. As oral paclitaxel is Cremophor-free there is no need for pretreatment for infusion reactions. While targeted therapies have improved outcomes in patients with HER2+ tumors there is still an unmet need for therapies that prolong survival with reduced toxicity across all tumor subtypes. Methods: A phase 3, open-label, randomized, multicenter study in women with histologically- or cytologically-confirmed MBC for whom treatment with IV paclitaxel monotherapy had been recommended by their oncologist randomized 402 patients 2:1 to either oral paclitaxel and encequidar (oPac+E) or IV paclitaxel (IVPac). Oral paclitaxel 205 mg/m 2 was administered once daily for 3 consecutive days, weekly. Encequidar 12.9 mg was administered 1 hour before each dose of oral paclitaxel. IV paclitaxel 175 mg/m 2 was infused over 3 hours on day 1 of every 3 weeks. Results: In the ITT population oPac+E was superior to IV paclitaxel with a confirmed tumor response rate of 35.8% vs 23.4% for IVPac: a difference of 12.4% (p = 0.0107). A post-hoc subgroup efficacy analysis was conducted based on tumor subtypes, however, the study was not powered to detect statistical differences within these subgroups. Patients in the HR+/HER2- subgroup had a better tumor response to oPac+E (44.8% vs 21.4% IVPac-response rate difference of 23.4%) as did patients in the TNBC (30.5% vs 20.2%-response rate difference of 10.3%) subgroup. Responses were similar (49% vs 47.4% IVPac) in the HER2+ subgroup. Patients with unknown HER2 status receiving oPac+E had a 58.8% response rate vs 14.3% with IVPac (response rate difference of 44.5%). Conclusions: oPac+E is the first oral taxane to demonstrate superiority in radiologically confirmed tumor response rate compared to IVPac in a group of 402 women with metastatic breast cancer. Patients with HR+/HER2-, TNBC, and Unknown subtypes responded considerably better to oPac+E vs IVPac—especially the HR+/HER2- subtype which represented 63% of the patients treated with oPac+E and 55% of the patients treated with IVPac. Clinical trial information: NCT 02594371 ." @default.
• W3170446002 created "2021-06-22" @default.
• W3170446002 creator A5015153861 @default.
• W3170446002 creator A5015685796 @default.
• W3170446002 creator A5022916059 @default.
• W3170446002 creator A5048927194 @default.
• W3170446002 creator A5053649594 @default.
• W3170446002 creator A5057161101 @default.
• W3170446002 creator A5060759473 @default.
• W3170446002 creator A5062096307 @default.
• W3170446002 creator A5068039027 @default.
• W3170446002 creator A5078171621 @default.
• W3170446002 creator A5090188675 @default.
• W3170446002 creator A5091174943 @default.
• W3170446002 date "2021-05-20" @default.
• W3170446002 modified "2023-09-27" @default.
• W3170446002 title "Confirmed tumor response by molecular subtype in patients with metastatic breast cancer: Sub-analysis from a phase 3 clinical study comparing oral paclitaxel and encequidar to IV paclitaxel." @default.
• W3170446002 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.1073" @default.
• W3170446002 hasPublicationYear "2021" @default.
• W3170446002 type Work @default.
• W3170446002 sameAs 3170446002 @default.
• W3170446002 citedByCount "1" @default.
• W3170446002 countsByYear W31704460022022 @default.
• W3170446002 crossrefType "journal-article" @default.
• W3170446002 hasAuthorship W3170446002A5015153861 @default.
• W3170446002 hasAuthorship W3170446002A5015685796 @default.
• W3170446002 hasAuthorship W3170446002A5022916059 @default.
• W3170446002 hasAuthorship W3170446002A5048927194 @default.
• W3170446002 hasAuthorship W3170446002A5053649594 @default.
• W3170446002 hasAuthorship W3170446002A5057161101 @default.
• W3170446002 hasAuthorship W3170446002A5060759473 @default.
• W3170446002 hasAuthorship W3170446002A5062096307 @default.
• W3170446002 hasAuthorship W3170446002A5068039027 @default.
• W3170446002 hasAuthorship W3170446002A5078171621 @default.
• W3170446002 hasAuthorship W3170446002A5090188675 @default.
• W3170446002 hasAuthorship W3170446002A5091174943 @default.
• W3170446002 hasConcept C121608353 @default.
• W3170446002 hasConcept C126322002 @default.
• W3170446002 hasConcept C143998085 @default.
• W3170446002 hasConcept C181389837 @default.
• W3170446002 hasConcept C2775930923 @default.
• W3170446002 hasConcept C2776694085 @default.
• W3170446002 hasConcept C2777292972 @default.
• W3170446002 hasConcept C2908647359 @default.
• W3170446002 hasConcept C29730261 @default.
• W3170446002 hasConcept C530470458 @default.
• W3170446002 hasConcept C71924100 @default.
• W3170446002 hasConcept C90924648 @default.
• W3170446002 hasConcept C98274493 @default.
• W3170446002 hasConcept C99454951 @default.
• W3170446002 hasConceptScore W3170446002C121608353 @default.
• W3170446002 hasConceptScore W3170446002C126322002 @default.
• W3170446002 hasConceptScore W3170446002C143998085 @default.
• W3170446002 hasConceptScore W3170446002C181389837 @default.
• W3170446002 hasConceptScore W3170446002C2775930923 @default.
• W3170446002 hasConceptScore W3170446002C2776694085 @default.
• W3170446002 hasConceptScore W3170446002C2777292972 @default.
• W3170446002 hasConceptScore W3170446002C2908647359 @default.
• W3170446002 hasConceptScore W3170446002C29730261 @default.
• W3170446002 hasConceptScore W3170446002C530470458 @default.
• W3170446002 hasConceptScore W3170446002C71924100 @default.
• W3170446002 hasConceptScore W3170446002C90924648 @default.
• W3170446002 hasConceptScore W3170446002C98274493 @default.
• W3170446002 hasConceptScore W3170446002C99454951 @default.
• W3170446002 hasIssue "15_suppl" @default.
• W3170446002 hasLocation W31704460021 @default.
• W3170446002 hasOpenAccess W3170446002 @default.
• W3170446002 hasPrimaryLocation W31704460021 @default.
• W3170446002 hasRelatedWork W10233532 @default.
• W3170446002 hasRelatedWork W11467293 @default.
• W3170446002 hasRelatedWork W13154270 @default.
• W3170446002 hasRelatedWork W16661828 @default.
• W3170446002 hasRelatedWork W18214132 @default.
• W3170446002 hasRelatedWork W19355547 @default.
• W3170446002 hasRelatedWork W2011212 @default.
• W3170446002 hasRelatedWork W2976006 @default.
• W3170446002 hasRelatedWork W7849647 @default.
• W3170446002 hasRelatedWork W9309986 @default.
• W3170446002 hasVolume "39" @default.
• W3170446002 isParatext "false" @default.
• W3170446002 isRetracted "false" @default.
• W3170446002 magId "3170446002" @default.
• W3170446002 workType "article" @default.